Acute Myeloid Leukemia (non-APL) · line 1 · 7+3 + fractionated gemtuzumab ozogamicin (CD33+ AML, 1L; ALFA-0701)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-AML-7-3-GO |
| ID | IND-AML-1L-7-3-GO-CBF |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-30 | pending_clinical_signoff |
| Diseases | DIS-AML |
| Sources | SRC-ALFA-0701-CASTAIGNE-2012 SRC-ELN-AML-2022 SRC-NCCN-AML-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Aggressive-track 1L refinement of standard 7+3 for fit CD33+ AML with favorable / intermediate cytogenetics. Surfaced by curated case patient_aml_cbf_inv16_7_3_go.json which routed to IND-AML-1L-7-3 but flagged "no dedicated 7+3+GO indication in KB". Pairs with IND-AML-1L-7-3 (the parent indication for AML 1L without GO add- on); engine algorithm wiring to choose between the two based on CBF / cytogenetic risk + GO accessibility is engine work and out of scope for this commit.
Used By
Algorithms
ALGO-AML-1L- ALGO-AML-1L